Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 663,003
  • Shares Outstanding, K 397,008
  • Annual Sales, $ 583,190 K
  • Annual Income, $ 7,730 K
  • 60-Month Beta 1.85
  • Price/Sales 1.14
  • Price/Cash Flow 27.25
  • Price/Book 1.14
Trade AMRN with:

Options Overview Details

View History
  • Implied Volatility 114.68% ( -121.77%)
  • Historical Volatility 68.78%
  • IV Percentile 64%
  • IV Rank 10.78%
  • IV High 703.69% on 07/07/22
  • IV Low 43.48% on 11/03/21
  • Put/Call Vol Ratio 0.15
  • Today's Volume 3,450
  • Volume Avg (30-Day) 1,802
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 114,582
  • Open Int (30-Day) 103,958

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.07
  • Number of Estimates 6
  • High Estimate -0.02
  • Low Estimate -0.11
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2301 +32.51%
on 08/05/22
1.7100 -4.68%
on 08/16/22
+0.2800 (+20.74%)
since 07/15/22
3-Month
1.2000 +35.83%
on 07/01/22
2.0300 -19.70%
on 06/08/22
-0.0300 (-1.81%)
since 05/17/22
52-Week
1.1100 +46.85%
on 05/12/22
5.9700 -72.70%
on 08/23/21
-3.9800 (-70.94%)
since 08/17/21

Most Recent Stories

More News
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

AMRN : 1.6300 (-2.40%)
SRRK : 9.25 (-4.84%)
BNTX : 152.04 (-5.19%)
PLRX : 19.75 (-2.03%)
Does Amarin Deserve a Spot in Your Portfolio after Earnings ?

Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.

AMRN : 1.6300 (-2.40%)
INO : 2.53 (-6.64%)
Amarin (AMRN) Q2 2022 Earnings Call Transcript

AMRN earnings call for the period ending June 30, 2022.

AMRN : 1.6300 (-2.40%)
Why Investors Were Giving Amarin the Cold Shoulder Today

Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.

AMRN : 1.6300 (-2.40%)
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations...

AMRN : 1.6300 (-2.40%)
HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets,...

AMRN : 1.6300 (-2.40%)
HLS.TO : 12.45 (-4.16%)
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

LLY : 316.82 (+2.10%)
HZNP : 61.73 (-3.67%)
AMRN : 1.6300 (-2.40%)
BPMC : 61.17 (-10.77%)
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

AMGN : 250.58 (-1.02%)
HZNP : 61.73 (-3.67%)
AMRN : 1.6300 (-2.40%)
BPMC : 61.17 (-10.77%)
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets,...

AMRN : 1.6300 (-2.40%)
HLS.TO : 12.45 (-4.16%)
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a...

AMRN : 1.6300 (-2.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating...

See More

Key Turning Points

3rd Resistance Point 1.8667
2nd Resistance Point 1.7833
1st Resistance Point 1.7067
Last Price 1.6300
1st Support Level 1.5467
2nd Support Level 1.4633
3rd Support Level 1.3867

See More

52-Week High 5.9700
Fibonacci 61.8% 4.1135
Fibonacci 50% 3.5400
Fibonacci 38.2% 2.9665
Last Price 1.6300
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar